A compound selected from compounds of the following formula, and pharmaceutically acceptable salts, N-oxides, hydrates and solvates thereof: wherein: W is CRW, X is CRX, Y is CRY and Z is CRZ； or W is N, X is CRX, Y is CRY and Z is CRZ； or W is CRW, X is N, Y is CRY and Z is CRZ； or W is N, X is CRX, Y is CRY and Z is N； or W is CRW, X is N, Y is N and Z is CRZ； or W is N, X is CRX, Y is N and Z is CRZ； or W is N, X is N, Y is CRY and Z is CRZ； where: -RW is, independently, -H or -F； -RX is, independently, -H or -F； -RY is, independently, -H or -F； and -RZ is, independently, -H or -F； and where: -L3P- is, independently, a simple covalent bond or -L3PL-； where: -L3PL- is, independently, -L3PR1-, -C (>； = O) -, -L3PR2-C (>； = O) -, -S (>； = O) 2-, -L3PR3-S (>； = O) 2 or -O-L3PR4-； wherein: each -L3PR1- is linear or branched saturated C1-4 alkylene； each -L3PR2- is linear or branched saturated C1-4 alkylene； each -L3PR3- is linear or branched saturated C1-4 alkylene； each -L3PR4- is linear or branched saturated C1-4 alkylene； and where: -R3N is, independently, -NH2, -NHRA, -NRARB or -NRCRD； where: each -RA is, independently: -RA1, -RA2, -RA3, -RA4, -RA5, -LA-RA2, -LA-RA3, -LA-RA4 or -LA-RA5； each -RA1 is linear or branched saturated C1-6 alkyl, and is optionally substituted with one or more -RS1 groups； each -RA2 is saturated C3-6 cycloalkyl, and is optionally substituted with one or more -RS2C groups； each -RA3 is non-aromatic C3-7 heterocyclyl, and is optionally substituted on carbon with one or more -RS2C groups, and is optionally substituted on secondary nitrogen, if present, with a -RSN group； each -RA4 is, independently, phenyl or naphthyl, and is optionally substituted with one or more -RS3C groups； each -RA5 is C5-10 heteroaryl, and is optionally substituted on carbon with one or more -RS3C groups, and is optionally substituted on secondary nitrogen, if present, with a -RSN group； each -LA- is linear or branched saturated C1-4 alkylene；Un compuesto sele
